August 10, 2010

Jenner & Block Partner John J. Molenda will discuss “Critical Developments Affecting the Value of Biotech/Pharma Intellectual Property,” during Canaccord Genuity’s special “30th Annual Growth Conference,” being held on August 10 - 12, 2010 in Boston, MA. During this session Dr. Molenda will examine current trends in the acquisition and assertion of biotech/pharma patents and key decisions affecting biotech/pharma patent validity and enforceability. He will also provide a summary of legislation relating to biosimilars and patent reform.

This conference brings together some of the world’s most innovative companies and institutional investors to share knowledge, discuss emerging trends, build relationships, identify opportunities and ignite global ideas for growth. There are 300 companies presenting at the conference covering primarily the Life Sciences, Technology, and Sustainability sectors, with more than 1,300 attendees.

Dr. Molenda is a member of the Firm’s Litigation Department.  He is also a member of the Firm’s Intellectual Property, Appellate and Supreme Court, and Pharmaceutical, Biotech and Medical Devices Practices. In view of his background in pharmaceutical and biotech research, Dr. Molenda has acquired extensive experience in litigating patent cases in both of those fields.  With respect to pharmaceuticals, he has litigated numerous Hatch-Waxman and non-Hatch-Waxman cases on behalf of both brand and generic companies. With respect to biotechnology, he has represented clients litigating patents involving genetic engineering, molecular biology, and cell biology-related inventions. 

Please click here for more information.